Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials-Reference-Cited by-同舟云学术

Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials

Published:2022-10 Issue: Volume:174 Page:57-67
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Fulgenzi Claudia A.M.,D'Alessio Antonio^ORCID,Airoldi Chiara,Scotti Lorenza,Demirtas Coskun O.^ORCID,Gennari Alessandra,Cortellini Alessio^ORCID,Pinato David J.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

2. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study;Ren;Lancet Oncol,2021

3. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA;Abou-Alfa;J Clin Oncol,2022

4. Cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma: results from the randomized phase III COSMIC-312 trial;Kelley;Ann Oncol,2022

5. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update;Reig;J Hepatol,2022

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of FLNC and JUP variants causing arrhythmogenic cardiomyopathy in an Iranian family with different clinical features;BMC Cardiovascular Disorders;2024-08-23

2. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis;BMC Cancer;2024-08-14

3. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction;JAMA Oncology;2024-07-18

4. A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma;International Immunopharmacology;2024-06

5. The State of Systematic Therapies in Clinic for Hepatobiliary Cancers;Journal of Hepatocellular Carcinoma;2024-03